4 Benzyl-1,3-oxazolidin-2-one as a Multi-target Neuroprotective Candidate Against Parkinson’s Disease: An Integrative In Silico Study of Pharmacokinetics, Molecular Docking and Normal Mode Analysis
Biointerface Research in Applied Chemistry · 15.05.2026 · 16 (3)
DOI: 10.33263/briac163.091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biointerface Research in Applied Chemistry, online erschienen am 15.05.2026. Verfasst von Anish Singh und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss, oxidative stress, protein aggregation, and chronic neuroinflammation. Owing to the multifactorial nature of PD, multi-target small molecules with favorable pharmacokinetic and neuroprotective profiles are increasingly explored as therapeutic candidates. The present study evaluates the pharmacokinetic, toxicological, molecular docking, and molecular simulation properties of the 4-Benzyl-1,3-oxazolidin-2-one heterocyclic scaffold, with potential neuroprotective relevance. ADMET predictions (pkCSM, SwissADME) revealed excellent gastrointestinal absorption, blood-brain barrier (BBB) permeability, moderate plasma protein binding, and a predictable metabolic profile, with overall non-carcinogenic and non-cardiotoxic toxicity parameters. In molecular docking analysis, 4-Benzyl-1,3-oxazolidin-2-one demonstrated moderate binding affinity toward NF-κB (-5.5 kcal/mol), TNF-α (-6.2 kcal/mol), α-synuclein (-5.1 kcal/mol), and the dopamine receptor (-7.6 kcal/mol). However, its docking scores were comparatively lower than those of standard ligands, including parthenolide, adalimumab, anle-138B, and bromocriptine, suggesting relatively weak binding interactions across the selected targets and potential multi-target modulatory activity. Normal Mode Analysis, B-factor evaluation, RMSF, eigenvalue profiling, and covariance mapping revealed distinct binding dynamics, with the compound stabilizing dopamine-associated protein environments more strongly than intrinsically disordered α-synuclein. Collectively, these integrated computational findings suggest that 4-Benzyl-1,3-oxazolidin-2-one exhibits promising pharmacokinetic, anti-inflammatory, and anti-aggregation attributes, supporting its candidacy as a multi-target therapeutic lead for further investigation in PD.
Zitieren
APA
Singh, A., Dalal, D., & Singh, L. (2026). 4 Benzyl-1,3-oxazolidin-2-one as a Multi-target Neuroprotective Candidate Against Parkinson’s Disease: An Integrative In Silico Study of Pharmacokinetics, Molecular Docking and Normal Mode Analysis. Biointerface Research in Applied Chemistry, 16(3). https://doi.org/10.33263/briac163.091
Vancouver
Singh A, Dalal D, Singh L. 4 Benzyl-1,3-oxazolidin-2-one as a Multi-target Neuroprotective Candidate Against Parkinson’s Disease: An Integrative In Silico Study of Pharmacokinetics, Molecular Docking and Normal Mode Analysis. Biointerface Research in Applied Chemistry. 2026;16(3). doi:10.33263/briac163.091
BibTeX
@article{Singh2026,
author = {Singh, Anish and Dalal, Diksha and Singh, Lovedeep},
title = {4 Benzyl-1,3-oxazolidin-2-one as a Multi-target Neuroprotective Candidate Against Parkinson’s Disease: An Integrative In Silico Study of Pharmacokinetics, Molecular Docking and Normal Mode Analysis},
journal = {Biointerface Research in Applied Chemistry},
year = {2026},
volume = {16},
number = {3},
doi = {10.33263/briac163.091}
}
EUVIMED